Monoclonal antibodies to human CD6
US6372215B1 · kind B1 · utility
13Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 1998 |
| Grant date | Apr 16, 2002 |
| Priority date | — |
| Expiry date | Feb 25, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/864
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antibodies and other binding agents that bind specifically to SRCR domains of human CD6 (hCD6) and have advantageous properties, including the capacity to substantially inhibit binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. The binding agents of the invention are useful, inter alia, in methods for screening peptides and drugs that also bind to hCD6 and/or modulate ALCAM binding to hCD6, as well as in diagnostic and therapeutic methods for management and treatment of inflammatory and autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.